bioAffinity Technologies Reports 146% CyPath® Lung Sales Growth Amid Strategic Pivot
Event summary
- CyPath® Lung unit sales surged 146% year-over-year in Q1 2026, with testing revenue up 114% to $361,000.
- Total revenue declined 27% to $1.4 million due to discontinuation of unprofitable pathology services.
- Company launched a large-scale longitudinal clinical trial with U.S. Department of Defense support.
- Brooke Army Medical Center initiated a 40-patient study using bioAffinity's technology for asthma/COPD treatment guidance.
- Three new patient case studies demonstrated CyPath® Lung's ability to avoid unnecessary biopsies.
The big picture
bioAffinity's strategic pivot to focus on higher-margin CyPath® Lung testing is showing early commercial traction, with accelerating physician adoption and expanding clinical use. The company's partnership with military healthcare institutions positions it to potentially set new diagnostic standards in lung cancer detection. Success will depend on maintaining this momentum while managing cash burn, as Q1 2026 saw a 50% reduction in cash reserves from year-end 2025.
What we're watching
- Commercial Execution
- Whether bioAffinity can sustain its 69% increase in physician adopters and expand into new geographic markets.
- Clinical Validation
- The pace at which the longitudinal clinical trial with military/VA institutions will establish CyPath® Lung as standard of care.
- Pipeline Development
- How quickly bioAffinity can advance its diagnostic platform for asthma and COPD treatments beyond the current lung cancer focus.
Related topics